While surgical resection of the underlying tumor is usually the first-line treatment for patients with endogenous CS [22], [23], after failed surgery, tumor recurrence, or in patients not eligible for surgery, pharmacological reduction of cortisol activity can also be achieved with GR antagonists. This evidence concerns the gene NR3C1 and Cowden syndrome 1.